Leveljump Health Stock Price, News & Analysis

LevelJump Healthcare Corp (JMPHF) received a notice of requisition on November 3, 2025 requesting a shareholders' meeting under section 105(1) of the Business Corporations Act (Ontario).

The Requisition, submitted by Frank Teti and Franmar Properties Ltd., seeks to: (i) remove all five incumbent directors and (ii) elect five named nominees — Claude Ayache, Rob Saltsman, Jeff Stevens, Sheldon Levy, and Tasheel Jeerh. The company said it is reviewing the Requisition and will respond within the time required by the Act.

LevelJump Healthcare (OTC: JMPHF) announced trading on the TSX Venture Exchange is expected to resume on or about October 9, 2025. The company says 12 months of disclosure including an annual information form are available on SEDAR+ and its website.

Key corporate updates include director re-elections at the September 4, 2025 AGM, Exchange acceptance notices for existing management consulting agreements, and insider loans totaling an aggregate requested maximum of $1,900,000 (with $65,288 advanced against the additional $309,457 request). The company filed interim June 30, 2025 financials showing a $2,637,203 working capital deficiency and canceled a planned purchase of its leased headquarters.

LevelJump Healthcare (TSXV: JUMP) has released its Q2 2025 financial results, showing consistent growth in revenues and operational performance. The company reported Q2 2025 revenues of $4.7 million, up 6.2% from the previous year, and six-month revenues of $9.3 million, representing a 9.4% increase year-over-year.

The company's subsidiary, Canadian Teleradiology Services, achieved an EBITDA of $1.01 million in Q2 and $2.23 million for the six-month period. Additionally, LevelJump is proceeding with its previously announced acquisition of two diagnostic imaging clinics in Calgary, with the transaction expected to close by October 2025.

LevelJump Healthcare (TSXV: JUMP) has announced that the Ontario Securities Commission (OSC) has revoked its Failure-to-File Cease Trade Order (FFCTO) that was issued on May 7, 2025. The company has now met all continuous disclosure obligations under securities legislation and is actively seeking reinstatement of trading on the TSX Venture Exchange.

The company will issue a news release before trading resumes.

LevelJump Healthcare Corp. reported strong Q1 2025 financial results with revenues of $4.58 million, representing a 12.8% increase from Q1 2024's $4.06 million. The company achieved a net profit of $200,566 and EBITDA of $898,017. Its subsidiary, Canadian Teleradiology Services, contributed $1.03 million in EBITDA. The company expects the revocation of a cease trade order after becoming current with disclosure obligations. Additionally, LevelJump has agreed to acquire two diagnostic imaging clinics in Calgary, with the deal expected to close in July 2025. The company anticipates trading reinstatement on the TSX Venture Exchange once the cease trade order is lifted.

LevelJump Healthcare Corp. reported strong financial results for 2024, with revenues reaching $17.7 million, representing a 41% increase from $12.6 million in 2023. The company's Q4 2024 revenue was $4.8 million with a net profit of $1.95 million, while the full-year net profit stood at $1.2 million. Canadian Teleradiology Services, their wholly-owned subsidiary, achieved EBITDA of $3.35 million. The company reported full-year EBITDA of $1.54 million, with Q4 EBITDA at $395,936. LevelJump is currently interpreting imaging scans for approximately 200,000 patients annually. Post year-end, the company announced plans to acquire two diagnostic imaging outpatient clinics in Calgary, Alberta, with the transaction expected to close by July 2025.

LevelJump Healthcare's subsidiary CTS has signed a definitive agreement to acquire two diagnostic imaging clinics in Calgary, Alberta for $1.92 million in cash. The IHFs provide x-ray, ultrasound, and mammography services, generating combined revenue of $2.2 million and EBITDA of $500,000. The acquisition, expected to close in July 2025, is subject to regulatory approval, due diligence, and securing institutional financing. Additionally, the company announced a delay in filing its 2024 year-end reporting documents, now expected within 7-10 days, after which it will seek to lift the current cease trade order and reinstate trading on TSX Venture Exchange.

LevelJump Healthcare has announced a delay in filing its annual audited financial statements for the fiscal year ending December 31, 2024. The company expects a cease trade order from the Ontario Securities Commission due to missing the April 30, 2025 deadline.

The delay stems from the company's significant growth, with gross revenues increasing over 30% between September 2023 and September 2024, primarily due to Alberta acquisitions. To address these challenges, LevelJump has:

• Implemented new accounting software and controls
• Engaged Ernst & Young as external consultants
• Made improvements following OSC's disclosure review

LevelJump expects to file the required documents within 30 days after the deadline and plans to apply for reinstating its TSX Venture Exchange listing afterward.

LevelJump Healthcare Corp. (TSXV: JUMP) announces the Ontario Securities Commission has revoked the failure-to-file cease trade order (FFCTO) issued on May 7, 2024. The FFCTO was initially imposed due to the company's failure to file required annual financial statements and documentation for 2023.

Following a continuous disclosure review, LevelJump has:

• Refiled MD&A for year-end 2023
• Refiled interim financials for Q1 and Q2 2024
• Filed CEO/CFO certifications
• Refiled Annual Information Form
• Filed Q3 2024 financials

The company has committed to holding a shareholder meeting within three months of the FFCTO revocation. LevelJump's core business remains focused on providing telehealth solutions and in-person radiology services through its diagnostic centres. The company will now seek trading resumption approval from the TSX Venture Exchange.